Table 4. Estimated costs of anti-HAT drugs consumed in the Democratic Republic of Congo from 2001 to 2003, based on observed number of patients treated by regimen*†.
| Drug | Observed no. patients treated | Drug quantity/patient required | Total quantity drugs required | Unit price‡ US$ | Total (US$) |
|---|---|---|---|---|---|
| Pentamidine | 13,957 | 8 | 111,656 | 2 | 223,312 |
| Suramin | 2,604 | 6 | 15,624 | 7 | 109,368 |
| Pentamidine-suramin | 104 | 8 | 832 | 2 | 1,664 |
| 6 | 624 | 7 | 4,368 | ||
| Melarsoprol | 24,456 | 9 | 220,104 | 7 | 1,540,728 |
| Eflornithine | 377 | 14 | 5,278 | 22 | 116,116 |
| Nifurtimox§ | 1,168 | 100 | 116,800 | 0 | 0 |
| Melarsoprol-nifurtimox | 1,581 | 4 | 6,324 | 7 | 44,268 |
| 64 | 101,184 | 0 | 0 | ||
| Total | 44,247 | 2,039,824 |
*HAT, human African trypanosomiasis. †Source of data: Programme National de Lutte contre la THA (PNLTHA) annual reports. The price of drugs is based on prices reported by the World Health Organization, 1998. Data for the HAT cases retreated in 2003 are not available. ‡Preferential price applicable during the period. §PNLTHA did not buy nifurtimox in this period.